HUP0001181A2 - Mikrorészecske formájú tetrahidropiridinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

Mikrorészecske formájú tetrahidropiridinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0001181A2
HUP0001181A2 HU0001181A HUP0001181A HUP0001181A2 HU P0001181 A2 HUP0001181 A2 HU P0001181A2 HU 0001181 A HU0001181 A HU 0001181A HU P0001181 A HUP0001181 A HU P0001181A HU P0001181 A2 HUP0001181 A2 HU P0001181A2
Authority
HU
Hungary
Prior art keywords
micro
pharmaceutical compositions
compositions containing
particulate form
tetrahydropyridin
Prior art date
Application number
HU0001181A
Other languages
English (en)
Inventor
Antoine Caron
Jean-Pierre Chambon
Olivier Monnier
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HUP0001181A2 publication Critical patent/HUP0001181A2/hu
Publication of HUP0001181A3 publication Critical patent/HUP0001181A3/hu
Publication of HU224348B1 publication Critical patent/HU224348B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

A találmány tárgya 1-[2-(2-naftil)-etil]-4-(3-trifluor-metil-fenil)-1,2,3,6-tetrahidropiridin-hidroklorid mikrorészecskeforma, amelylegalább 55%-ban 50 mm-nél kisebb átmérőjű részecskékből áll, továbbáaz ezt tartalmazó gyógyszerkészítmény. Ó
HU0001181A 1996-12-23 1997-12-23 Mikrorészecske formájú tetrahidropiridinszármazékok, és a vegyületeket tartalmazó gyógyszerkészítmények HU224348B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615905A FR2757510B1 (fr) 1996-12-23 1996-12-23 Forme microparticulaire d'un derive de tetrahydropyridine
PCT/FR1997/002394 WO1998028272A1 (fr) 1996-12-23 1997-12-23 Forme microparticulaire d'un derive de tetrahydropyridine

Publications (3)

Publication Number Publication Date
HUP0001181A2 true HUP0001181A2 (hu) 2000-11-28
HUP0001181A3 HUP0001181A3 (en) 2003-03-28
HU224348B1 HU224348B1 (hu) 2005-08-29

Family

ID=9499044

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001181A HU224348B1 (hu) 1996-12-23 1997-12-23 Mikrorészecske formájú tetrahidropiridinszármazékok, és a vegyületeket tartalmazó gyógyszerkészítmények

Country Status (38)

Country Link
US (4) US20020028247A1 (hu)
EP (1) EP0950051B1 (hu)
JP (2) JP4422214B2 (hu)
KR (1) KR100455797B1 (hu)
CN (1) CN1088698C (hu)
AR (1) AR009673A1 (hu)
AT (1) ATE250032T1 (hu)
AU (1) AU730302B2 (hu)
BR (1) BR9714177A (hu)
CA (1) CA2275593C (hu)
CO (1) CO4920213A1 (hu)
CZ (1) CZ294272B6 (hu)
DE (1) DE69724999T2 (hu)
DK (1) DK0950051T3 (hu)
DZ (1) DZ2386A1 (hu)
EE (1) EE04112B1 (hu)
EG (1) EG24749A (hu)
ES (1) ES2207758T3 (hu)
FR (1) FR2757510B1 (hu)
HK (1) HK1024000A1 (hu)
HU (1) HU224348B1 (hu)
IL (1) IL129937A (hu)
IN (1) IN186977B (hu)
IS (1) IS2064B (hu)
MY (1) MY126298A (hu)
NO (1) NO311569B1 (hu)
NZ (1) NZ336129A (hu)
PL (1) PL190098B1 (hu)
PT (1) PT950051E (hu)
RU (1) RU2193031C2 (hu)
SI (1) SI0950051T1 (hu)
SK (1) SK283917B6 (hu)
TR (1) TR199901362T2 (hu)
TW (1) TW534820B (hu)
UA (1) UA66776C2 (hu)
WO (1) WO1998028272A1 (hu)
YU (1) YU49427B (hu)
ZA (1) ZA9711579B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4570357B2 (ja) * 2001-07-06 2010-10-27 ライフサイクル ファーマ エー／エス 制御された凝集
BE1015641A4 (fr) * 2003-05-26 2005-07-05 Mariani Jean Paul Micronisation 70.
RU2472490C1 (ru) * 2011-08-05 2013-01-20 Открытое акционерное общество "Биосинтез" Средство для лечения кожных гнойных инфекций, составы и способы получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562883A (en) * 1896-06-30 Thill-coupling
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
CA2126685C (en) * 1992-10-26 2002-07-23 Bruno Gander Process for the production of microcapsules
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US6489334B2 (en) * 1996-12-23 2002-12-03 Sanofi-Synthelabo Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors

Also Published As

Publication number Publication date
SI0950051T1 (en) 2004-02-29
JP2001507013A (ja) 2001-05-29
CN1088698C (zh) 2002-08-07
DE69724999T2 (de) 2004-07-22
IL129937A0 (en) 2000-02-29
CO4920213A1 (es) 2000-05-29
HU224348B1 (hu) 2005-08-29
HK1024000A1 (en) 2000-09-29
YU28899A (sh) 2000-03-21
CZ229199A3 (cs) 1999-09-15
AR009673A1 (es) 2000-04-26
DK0950051T3 (da) 2004-01-26
NO311569B1 (no) 2001-12-10
RU2193031C2 (ru) 2002-11-20
JP2009280581A (ja) 2009-12-03
TR199901362T2 (xx) 1999-09-21
US20020192292A1 (en) 2002-12-19
CN1241179A (zh) 2000-01-12
EE04112B1 (et) 2003-08-15
ES2207758T3 (es) 2004-06-01
NO993077D0 (no) 1999-06-22
FR2757510B1 (fr) 2000-01-07
EE9900263A (et) 2000-02-15
DZ2386A1 (fr) 2002-12-28
EP0950051B1 (fr) 2003-09-17
ATE250032T1 (de) 2003-10-15
KR20000069503A (ko) 2000-11-25
CA2275593C (en) 2005-12-20
IN186977B (hu) 2001-12-22
BR9714177A (pt) 2000-02-29
CZ294272B6 (cs) 2004-11-10
US20020028247A1 (en) 2002-03-07
JP4422214B2 (ja) 2010-02-24
PL190098B1 (pl) 2005-10-31
TW534820B (en) 2003-06-01
DE69724999D1 (de) 2003-10-23
YU49427B (sh) 2006-01-16
KR100455797B1 (ko) 2004-11-06
SK82999A3 (en) 1999-12-10
PL334276A1 (en) 2000-02-14
ZA9711579B (en) 1998-06-25
PT950051E (pt) 2004-02-27
UA66776C2 (uk) 2004-06-15
EP0950051A1 (fr) 1999-10-20
US20100021541A1 (en) 2010-01-28
IL129937A (en) 2002-09-12
AU730302B2 (en) 2001-03-01
WO1998028272A1 (fr) 1998-07-02
US20080255365A1 (en) 2008-10-16
SK283917B6 (sk) 2004-05-04
CA2275593A1 (en) 1998-07-02
FR2757510A1 (fr) 1998-06-26
IS5077A (is) 1999-06-10
AU5668598A (en) 1998-07-17
IS2064B (is) 2005-11-15
NO993077L (no) 1999-06-22
HUP0001181A3 (en) 2003-03-28
MY126298A (en) 2006-09-29
NZ336129A (en) 2000-11-24
EG24749A (en) 2010-07-20

Similar Documents

Publication Publication Date Title
HUP9701281A3 (en) Piperidine derivatives as neurokinin antagonists and pharmaceutical compositions containing them
CY1115589T1 (el) Φαρμακευτικες συνθεσεις για την προληψη και αγωγη των διαταραχων του κεντρικου νευρικου συστηματος περιλαμβανοντας μια νικοτινικη ενωση και εναν αναστολεα ακετυλχολινεστερασης
BG105556A (en) New esters derived from substituted phenyl-cyclohexyl compounds
CY1108348T1 (el) Υποκατεστημενα 2-(2,6-διοξοπιπεριδιν-3-υλ)-φθαλιμιδια και μεθοδος μειωσης των tnf αλφα επιπεδων
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
EP1567161A4 (en) PHARMACEUTICAL COMPOSITION OF 1- (3,4-DIMETHOXYPHENYL) -4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE AND ITS USE
HUP0000487A2 (hu) Neurokinin antagonistaként alkalmazható szubsztituált oximszármazékok
IL135800A0 (en) Methods and pharmaceutical compositions for the closure of retinal breaks
IL119647A (en) Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it
EE9700202A (et) Diasendatud 1,4-piperidiini estrid ja amiidid, mis omavad 5-HT4 antagonistlikku aktiivsust
HUP0000088A3 (en) N-substituted azaheterocyclic compounds, process for producing them and pharmaceutical compositions containing them
HUP9802945A3 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
HK1044145A1 (zh) N-(2-苯基-4-氨基丁基)-1-萘甲酰胺作為神經激肽-1受體拮抗劑
HUP0001181A2 (hu) Mikrorészecske formájú tetrahidropiridinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
TNSN04077A1 (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof
EE04235B1 (et) Toimeainete, nimelt tetrahüdropüridiinide ja atsetüülkoliinesteraasi inhibiitorite, kombinatsioon Alzheimeri tõve tüüpi seniildementsuse raviks
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
HUP9900863A3 (en) 4,4-(disubstituted)cyclohexan-1-ol derivatives pharmaceutical compositions containing these compounds and use thereof
MXPA02007005A (es) Pseudopolimorfo de (-) -cis-2 -(2-clorofenil) -5, 7-dihidorxi -8[4r-(3s-hidroxi -1-meitl) piperidinil] -4h-1-benzopiran -4-ona.
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
TH34531A (th) อนุภาคขนาดเล็กมากที่ได้จากอนุพันธ์เตตราไฮโดรพิริดีน
HUP9902445A3 (en) Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine and pharmaceutical compositions containing them for the treatment of thrombosis disorders
BR9814414A (pt) "composição farmacêutica bebìvel"

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050620

MM4A Lapse of definitive patent protection due to non-payment of fees